Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 1
1948 8
1949 3
1950 4
1951 4
1952 7
1953 12
1954 6
1955 9
1956 13
1957 18
1958 7
1959 12
1960 13
1961 27
1962 36
1963 80
1964 93
1965 123
1966 104
1967 129
1968 181
1969 165
1970 196
1971 194
1972 194
1973 177
1974 158
1975 188
1976 199
1977 148
1978 150
1979 140
1980 165
1981 155
1982 199
1983 239
1984 231
1985 225
1986 244
1987 230
1988 227
1989 228
1990 235
1991 272
1992 249
1993 241
1994 235
1995 336
1996 326
1997 347
1998 386
1999 399
2000 389
2001 438
2002 414
2003 431
2004 466
2005 499
2006 530
2007 488
2008 466
2009 450
2010 445
2011 472
2012 418
2013 430
2014 458
2015 480
2016 485
2017 465
2018 494
2019 458
2020 449
2021 500
2022 488
2023 462
2024 228

Text availability

Article attribute

Article type

Publication date

Search Results

17,929 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for prasterone
Your search for oralsterone retrieved no results
Prasterone (Intrarosa) for Dyspareunia.
Hayes R, Birch M. Hayes R, et al. Am Fam Physician. 2019 Jan 15;99(2):117-122. Am Fam Physician. 2019. PMID: 30633482 Free article. Review. No abstract available.
Prasterone for vulvar and vaginal atrophy.
[No authors listed] [No authors listed] Drug Ther Bull. 2019 Dec;57(12):185-188. doi: 10.1136/dtb.2019.000034. Epub 2019 Oct 2. Drug Ther Bull. 2019. PMID: 31578208 Review. No abstract available.
Prasterone.
Kocis P. Kocis P. Am J Health Syst Pharm. 2006 Nov 15;63(22):2201-10. doi: 10.2146/ajhp060100. Am J Health Syst Pharm. 2006. PMID: 17090740 Review.
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration, and safety issues related to the use of prasterone are discussed. SUMMARY: Prasterone is a proprietary synthetic dehydroe
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects and toxicities, drug interactions, dosage and administration …
Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA. Heo YA. Drugs Aging. 2019 Aug;36(8):781-788. doi: 10.1007/s40266-019-00693-6. Drugs Aging. 2019. PMID: 31290076
Intravaginal prasterone (Intrarosa()) is a synthetic form of DHEA indicated for the treatment of VVA in postmenopausal women presenting with moderate to severe symptoms in the EU; prasterone is also approved in the USA for the treatment of dyspareunia due to menopau …
Intravaginal prasterone (Intrarosa()) is a synthetic form of DHEA indicated for the treatment of VVA in postmenopausal women presenti …
Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10mug estradiol on symptoms of vulvovaginal atrophy.
Archer DF, Labrie F, Montesino M, Martel C. Archer DF, et al. J Steroid Biochem Mol Biol. 2017 Nov;174:1-8. doi: 10.1016/j.jsbmb.2017.03.014. Epub 2017 Mar 18. J Steroid Biochem Mol Biol. 2017. PMID: 28323042 Review.
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens (CEE) and estradiol (E(2)) on moderate to severe dyspareunia and/or vaginal dryness. ...Decreases over placebo ranged from 0.35 to 1.21 with …
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens …
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Portman DJ, Goldstein SR, Kagan R. Portman DJ, et al. Climacteric. 2019 Feb;22(1):65-72. doi: 10.1080/13697137.2018.1535583. Epub 2018 Dec 17. Climacteric. 2019. PMID: 30554531 Review.
The loss of sex steroids (e.g. estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman's general health and produces bothersome physical changes that may interfere with normal sexual and genitourinary functioning. ...Adrenal D …
The loss of sex steroids (e.g. estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman …
Dehydroepiandrosterone (DHEA): Pharmacological Effects and Potential Therapeutic Application.
Nenezic N, Kostic S, Strac DS, Grunauer M, Nenezic D, Radosavljevic M, Jancic J, Samardzic J. Nenezic N, et al. Mini Rev Med Chem. 2023;23(8):941-952. doi: 10.2174/1389557522666220919125817. Mini Rev Med Chem. 2023. PMID: 36121077 Review.
Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in primates, which is predominantly synthesized in the adrenal cortex. ...
Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in primates, which is predominantly synthesized in the adrenal cor
Dehydroepiandrosterone (DHEA): hypes and hopes.
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Rutkowski K, et al. Drugs. 2014 Jul;74(11):1195-207. doi: 10.1007/s40265-014-0259-8. Drugs. 2014. PMID: 25022952 Review.
Dehydroepiandrosterone (DHEA) and its sulfated form dehydroepiandrosterone sulfate (DHEAS) are the most abundant circulating steroid hormones in humans. ...
Dehydroepiandrosterone (DHEA) and its sulfated form dehydroepiandrosterone sulfate (DHEAS) are the most abundant circulating s
Prasterone (Intrarosa) for dyspareunia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-150. Med Lett Drugs Ther. 2017. PMID: 28880846 No abstract available.
Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
Mension E, Alonso I, Cebrecos I, Castrejon N, Tortajada M, Matas I, Gómez S, Ribera L, Anglès-Acedo S, Castelo-Branco C. Mension E, et al. Climacteric. 2022 Oct;25(5):476-482. doi: 10.1080/13697137.2022.2050208. Epub 2022 Mar 28. Climacteric. 2022. PMID: 35343852
OBJECTIVE: The aim of this pilot study is to assess the security and efficacy of vaginal prasterone (dehydroepiandrostenedione [DHEA]) in BCS treated with AIs. ...The patients were requested to attend seriated visits after the beginning of the prasterone treatment t …
OBJECTIVE: The aim of this pilot study is to assess the security and efficacy of vaginal prasterone (dehydroepiandrostenedione [DHEA] …
17,929 results
You have reached the last available page of results. Please see the User Guide for more information.